Marinomed Biotech AG confirmed its financial outlook for the fiscal year 2022: The Company expects continued growth of Carragelose revenues and a slight increase in R&D expenses, and consequently an operating loss for 2022. Marinomed plans to reach operating profitability in the medium term.